Jacob E Berchuck
Emory University Hospital/Winship Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jacob E Berchuck as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07860554 · Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerEmory University · not yet recruiting · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · fiscal years 2009 to 2026Named on NCT07860554
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:03 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun · 2021152 citationsRCR 7.1
- The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.Ann Oncol · 202483 citationsRCR 9.5
- Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol · 202216 citationsRCR 0.9